REGN9533

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

End-Stage Kidney Disease (ESKD)Healthy Volunteer

Phase 1

Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults

CompletedNCT06665828

Regeneron PharmaceuticalsHealthy Volunteer

Start: 2025-03-04End: 2026-01-29Updated: 2026-02-06

Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis

Not yet recruitingNCT07759167

Regeneron PharmaceuticalsEnd-Stage Kidney Disease (ESKD)

Start: 2026-09-09End: 2027-03-25Target: 36Updated: 2026-08-12